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Abstract
Background: In rat middle cerebral and mesenteric arteries the KCa2.3 component of endothelium-dependent
hyperpolarization (EDH) is lost following stimulation of thromboxane (TP) receptors, an effect that may contribute to the
endothelial dysfunction associated with cardiovascular disease. In cerebral arteries, KCa2.3 loss is associated with NO
synthase inhibition, but is restored if TP receptors are blocked. The Rho/Rho kinase pathway is central for TP signalling and
statins indirectly inhibit this pathway. The possibility that Rho kinase inhibition and statins sustain KCa2.3 hyperpolarization
was investigated in rat middle cerebral arteries (MCA).
Methods: MCAs were mounted in a wire myograph. The PAR2 agonist, SLIGRL was used to stimulate EDH responses,
assessed by simultaneous measurement of smooth muscle membrane potential and tension. TP expression was assessed
with rt-PCR and immunofluorescence.
Results: Immunofluorescence detected TP in the endothelial cell layer of MCA. Vasoconstriction to the TP agonist, U46619
was reduced by Rho kinase inhibition. TP receptor stimulation lead to loss of KCa2.3 mediated hyperpolarization, an effect
that was reversed by Rho kinase inhibitors or simvastatin. KCa2.3 activity was lost in L-NAME-treated arteries, but was
restored by Rho kinase inhibition or statin treatment. The restorative effect of simvastatin was blocked after incubation with
geranylgeranyl-pyrophosphate to circumvent loss of isoprenylation.
Conclusions: Rho/Rho kinase signalling following TP stimulation and L-NAME regulates endothelial cell KCa2.3 function. The
ability of statins to prevent isoprenylation and perhaps inhibit of Rho restores/protects the input of KCa2.3 to EDH in the
MCA, and represents a beneficial pleiotropic effect of statin treatment.
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Introduction
In rat middle cerebral arteries (MCA) endothelium-dependent
hyperpolarization (EDH) responses (commonly called endothelium
derived hyperpolarizing factor, EDHF, response) are observed in
the presence of NO synthase (NOS) inhibitors, and can be
abolished by inhibition of endothelial cell KCa3.1 (intermediate
conductance, IKCa) channels, irrespective of the agonist used to
stimulate EDH [1,2]. In most other arterial beds, inhibition of
both endothelial cell KCa3.1 and KCa2.3 (small conductance,
SKCa) is necessary for block of EDH [3]. However, the MCA does
expresses endothelial cell KCa2.3 [4,5] which contribute to EDH
in vessels still able to synthesise NO [5]. Following inhibition of
NO synthase, input from KCa2.3 to EDH responses is restored in
the middle cerebral artery by exposure to antagonists of
thromboxane receptors (TP) [6]. As TP stimulation suppresses
the KCa2.3 input to EDH in rat middle cerebral and mesenteric
arteries [6,7], endogenous stimulation may represent a significant
influence on KCa2.3 function in the vasculature. The mechanism
that ‘protects’ KCa2.3 function during NO signalling or TP
inhibition remains unclear.
NO could potentially protect KCa2.3 channel function by direct
interaction/stimulation of the channel [8]. Alternatively, NO
might inhibit the synthesis of metabolites that affect KCa channels
by binding to the heme groups of enzymes. For example, the
cytochrome P450 metabolite 20-HETE inhibits EDH responses in
coronary arteries [9]. Neither of these pathways is likely to explain
the ‘protective’ effect of NO in cerebral arteries, as hyperpolar-
ization evoked by exogenous NO is inhibited by the KCa1.1
blocker iberiotoxin and therefore does not involve KCa2.3 [10]
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and inhibition of 20-HETE synthesis did not influence KCa2.3
function [6]. However, as KCa2.3 function is restored by
antagonizing TP [6], NO may protect KCa2.3 function by PKG
dependent inhibition of these receptors [11] or by inhibiting the
generation of metabolites that could stimulate this receptor by
binding to heme groups [12].
A major signalling pathway associated with TP is activation of
Rho kinase [13]. TP are expressed primarily on the smooth muscle
cell layer but they can also be expressed in endothelial cells [14]. It
is likely that TP signalling in endothelial cells also involves Rho
kinase therefore they may regulate the KCa2.3 channels expressed
selectively in these cells. The role of Rho kinase signalling on
KCa2.3 channel function can be directly assessed using inhibitors
of this kinase but the statin class of drugs are also reported to have
effects on Rho mediated signalling. They improve endothelium-
dependent relaxation via a mechanism that involves inhibition of
Rho signalling [15], independently of their ability to lower
cholesterol.
The aims of the current study were 1) to investigate if disrupting
the Rho kinase pathway could protect KCa2.3 functionality
following TP stimulation; 2) to establish if inhibition of Rho
kinase signalling might restore the KCa2.3 component of the EDH
response suppressed by the presence of NOS inhibitors, and 3) to
assess if statins had a similar effects to inhibitors of Rho kinase.
Materials and Methods
Animals and Ethics Statement
Male Wistar rats (200–300 g) were humanely killed by cervical
dislocation following institutional guidelines for animal welfare
and schedule 1 of the Animals (scientific procedures) Act 1986.
The brain was removed and immediately placed in ice-cold Krebs
solution. Segments of the MCA (,2 mm long) were dissected and
stored in ice-cold Krebs for use within 30 min, with similar size
vessels used in all experimental groups.
Simultaneous Measurement of Membrane Potential and
Tension
Segments of MCA (internal diameter ,150 mm) were mounted
in a Mulvany-Halpern myograph (model 400A, Danish Myotech-
nology) in Krebs solution containing (mM): NaCl, 118.0; NaCO3,
24; KCl, 3.6; KH2PO4, 1.2; MgSO4?7H2O, 1.2; glucose, 11.0;
CaCl2, 2.5; gassed with 95% O2, 5% CO2 and maintained at
37uC. After equilibration for 20 min, vessels were tensioned to 1–
1.5 mN (approximates wall tension at 60 mmHg). Smooth muscle
tension was recorded with an isometric force transducer and
Powerlab software (ADI, Australia). Vessel viability was assessed
by adding exogenous K+ (15–55 mM, total K+ concentration);
only vessels developing tension of $3 mN were used. Endothelial
cell viability was assessed by the ability of the agonist of protease-
activated receptor 2 (PAR2) SLIGRL (serine, leucine, isoleucine,
glycine, arginine, leucine-NH2; 20 mM) to relax spontaneous tone
and to hyperpolarize the smooth muscle cell membrane by
.15 mV. A concentration of 20 mM SLIGRL was used in all
further experiments; our previous study characterized the potency
of this agent to evoke endothelium dependent relaxation and this
concentration evokes circa 75–80% of the maximal relaxation
response [1]. Use of this single concentration also minimises
potential desensitization of the PAR2 receptor.
In some experiments endothelium-dependent responses to
SLIGRL were obtained in vessels that were able to synthesize
NO but were pre-constricted to approximately 80% of maximal
tone (obtained with 55 mM K+) with varying concentrations of the
TP receptor agonist U46619 (circa 50–100 nM). Under these
conditions EDH was assessed in the presence of the KCa channel
blockers used at concentrations that should cause full channel
inhibition with no off target effects at other KCa channels with
respect to their published Ki values, apamin (KCa2.3, 100 nM)
[16], TRAM-34 (KCa3.1, 1 mM) [17] and iberiotoxin (KCa1.1,
100 nM) [18] Previous studies have shown that the order in which
these drugs are added has no effect on the experimental outcome
[1,5]. For clarity of presentation they were always added in the
order: 1) TRAM-34; 2) The combination of TRAM-34 and
apamin; 3) the combination of TRAM-34, apamin and iber-
iotoxin. The effect of KCa blockers on EDH responses was also
assessed after addition of inhibitors of Rho kinase (Y27632; 1 and
10 mM) [19], and HMG-CoA reductase (simvastatin; 0.1 and
1 mM). We did not routinely measure relaxation in vessels able to
synthesise NO, under these conditions maximal vasodilatation due
to NO release persists after hyperpolarization is blocked [5]. In all
other experiments, isolated EDH responses were obtained in the
presence of the NO synthase inhibitor L-NAME (100 mM). We
have previously reported that under these conditions only KCa3.1
contribute to EDH [1] thus the other KCa channel blockers were
added in the sequence detailed above only if the previous KCa
blocker(s) failed to prevent hyperpolarization. KCa channel
blockers were assessed against EDH responses to SLIGRL
(20 mM) in the presence of: 1. the Rho kinase inhibitors Y27632
(10 mM) [19] or SR5037 (1 mM) [20] as no kinase inhibitor is
100% selective we chose two structurally distinct inhibitors at
concentrations approximately 100 times their respective Ki/IC50
for Rho kinase to ensure full inhibition with minimal effects on
other, related kinases [19,20]; 2. the HMG-CoA inhibitors
simvastatin (0.1 and 1 mM) or lovastatin (100 nM).These concen-
trations of statins are similar to the concentrations found in human
plasma (circa 25–90 nM) [21] and are in line with their Ki values
of low to high nanomolar, reported in various rat cell types [22] In
some experiments, in the presence of L-NAME and simvastatin
(100 nM) the vessels were also incubated with the isoprenoid
geranylgeranyl-pyrophosphate (GGPP, 1 mM). The concentration
of GGPP used corresponds to those reported to reverse statin
mediated inhibition of RhoA in vascular endothelial cells [15,23]
Papaverine (150 mM) was added at the end of each experiment to
assess overall tone (previous experiments show this was sufficient to
give a maximal relaxation indistinguishable from that obtained in
the presence of zero calcium [24]. All drugs were allowed to
equilibrate for 20 min before vasodilator responses were stimulat-
ed. The statins and GGPP were incubated for .60 min; longer
than prenylation-dependent translocation of Rho measured in
cerebral artery smooth muscle cells [25]. In most experiments
smooth muscle membrane potential (Em) and tension were
measured simultaneously (except where stated) at a sample rate
of 100 Hz as previously described, using glass microelectrodes
(filled with 2 M KCl; tip resistance, 80–120 MV) to measure Em
[26].
Reverse Transcription-PCR
RNA from intact rat MCAs was isolated using Trizol (Life
Technologies Ltd., Paisley, UK) and was reverse-transcribed using
standard protocols with random hexamers and TaqMan reverse
transcription reagents (Life Technologies Ltd.). Subsequent PCR
reactions used primers specific for rat TP receptor (forward 59-
CTCCTGGTGCTTCTTGACTC-39; reverse 59-GAGCTGG-
GAAGTGAACCTTG-39) and KCa2.3 (forward 59-ACTTCAA-
CACCCGATTCGTC-39; reverse 59- TTGACACCCCT-
CAGTTGGTG-39). Control reactions omitted reverse
transcriptase. PCR products were separated by electrophoresis,
stained with ethidium bromide, and sequenced to confirm identity.
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Immunofluorescence
Sources of antibodies were as follows: mouse anti-rat Platelet/
endothelial cell adhesion molecule-1 (PECAM-1/CD31, TLD-
3A12, Millipore, Watford, UK); rabbit anti-mouse thromboxane
A2 receptor (101882; Cayman, Tallinn, Estonia) and donkey anti-
mouse Cy5 and anti-rabbit Rhodamine Red-X (Stratech Scientific
Limited, Newmarket, UK).
Arteries were cut longitudinally and pinned flat on sylgard
plates and fixed with 100 mM PBS, pH 7.4 containing 4%
paraformaldehyde (30 min, 4uC). Artery whole mounts were
washed in PBS containing 10% normal horse serum and 0.3%
Triton-X-100 (1 h, room temperature) and proteins localized
using primary antibodies: Thromboxane A2 receptor (1:100) and
PECAM-1 (CD31, 1:200) (24 h, 4uC). Whole mounts were washed
(1 h, room temperature), incubated with secondary antibodies
coupled to Rhodamine Red-X, or Cy5 (1:500, 2 h, room
temperature) and mounted in ProLongH Gold (Invitrogen, Paisley,
UK) which contains DAPI.
Whole mounts were observed with a Zeiss laser-scanning
confocal microscope (LSM Meta 510) using an EC Plan-
Neofluar 406/1.3 Oil DIC objective. Images were collected at
a zoom of 1.5 and an iris of ,3 mm, and at least five optical
sections were taken at intervals of 0.5 mm. Single sections are
shown. Images were processed using ImageJ and Adobe
Photoshop software. The specificity of the immunostaining was
evaluated by omission of the primary antibody and processed as
above. Under these conditions, no staining was observed in any
experimental situation.
Data Analysis and Statistical Procedure
Results are expressed as the mean6s.e.mean of n animals.
Tension values are given in mN (always per 2 mm segment) and
Em as mV. Vasodilatation is expressed as percentage reduction of
the total vascular tone (spontaneous tone plus vasoconstrictor
response), quantified by relaxation with papaverine (150 mM).
Graphs were drawn and comparisons made using one-way
ANOVA with Tukeys’ post-test (Prism, Graphpad). P#0.05 was
considered significant. pEC50 values were calculated using non-
linear regression fitted to the Hill equation with variable slope
(Prism, Graphpad).
Drugs, Chemicals, Reagents and Other Materials
Exogenous K+ was added as an isotonic physiological salt
solution in which all the NaCl was replaced with an equivalent
amount of KCl. Concentrations of K+ used are expressed as
final bath concentration. GGPP, L-NAME (NG-nitro-L-arginine
methyl ester), papaverine HCl, TRAM-34 (1-[(2-Chlorophenyl)-
diphenylmethyl]-1H-pyrazole), U46619 (9,11-Dideoxy-11a,9a-
epoxymethanoprostaglandin F2a) and Y27632 ((R)-(+)-trans-4-
(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide dihydro-
chloride) were all obtained from Sigma (Poole, U.K.). Apamin
and iberiotoxin, from Latoxan (Valence, France). SLIGRL-NH2
from Auspep (Parkville, Australia). Simvastatin and Lovastatin
were from Cayman-Europe (Tallinn, Estonia). SR5037 ((R)-6-
Methoxy-N-(2-(1-methylpiperidin-4-yloxy)-4-(1H-pyrazol-4-yl)-
phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide) was a
generous gift from Professor Phil LoGrasso (Scripps Research
Institute, Florida, USA). All stock solutions (100 mM) were
prepared in dimethylsulfoxide except L-NAME, apamin, iber-
iotoxin, papaverine and SLIGRL which were dissolved in 0.9%
NaCl. Controls included appropriate vehicle. All blocking drugs
were used at appropriate concentrations to ensure full inhibition
of their target (normally 10–100 times the Ki/IC50 value) and
minimal off target effects and are the recommended selective
inhibitors as classified by IUPHAR [27].
Results
Thromboxane Receptors are Expressed in Endothelial
Cells of Middle Cerebral Arteries
While TP receptors are known to be expressed in human
endothelial cells derived from umbilical or saphenous veins [14],
expression has never been demonstrated in the endothelium of the
rat MCA. We examined expression of TP receptors and KCa2.3 in
the MCA by RT-PCR (Figure 1A). We amplified mRNA
transcripts of expected sizes and confirmed identity by sequencing.
Next, we examined expression of TP receptors in whole mount
preparations of rat MCA using immunofluorescence and confocal
microscopy. We detected TP receptor-immunoreactivity in the
endothelial cell layer (PECAM-1-positive) of rat MCA (Figure 1B–
E). Nuclei orientation was confirmed using DAPI, with endothelial
cell nuclei orientated in the horizontal plane, smooth muscle cell
nuclei in the vertical. TP receptor-immunoreactivity was also
detected in the smooth muscle cell layer (PECAM-1-negative)
(data not shown). Together, these data suggest that TP receptors
are appropriately localized on endothelial cells to regulate KCa2.3
channel function.
Inhibiting Rho Kinase Prevents Loss of KCa2.3 Input to
EDH during TP Receptor Stimulation
In the absence of a NO synthase inhibitor, the thromboxane
mimetic U46619 evoked concentration dependent constriction
(pEC50 = 7.6960.08, n = 5; Figure 2A). The selective Rho kinase
inhibitor Y27632 concentration-dependently inhibited this
response (pEC50 = 7.4560.15 and 7.0260.14, in presence of 1
and 10 mM Y27632, respectively, n = 5, P,0.05, Figure 2A).
Y27632 (10 mM) also significantly reduced the maximum
constriction produced by U46619 (control, 96.164.6%; 10 mM
Y27632, 26.465.7%, n= 5, P,0.05; Figure 2A).
When MCAs are able to synthesise NO, EDH is mediated by
both KCa2.3 and KCa3.1 with a small NO mediated KCa1.1
component [6,10]. Under similar conditions in the present
study, excepting that 100 nM U46619 was present to stimulate
TP receptors, SLIGRL-evoked EDH (25.462.5 mV, n= 5) was
partially blocked by the KCa3.1 inhibitor TRAM-34 (1 mM;
hyperpolarization of 11.660.9 mV, n= 5, P,0.05) and the
subsequent application of the KCa2.3 blocker apamin (100 nM)
had no further effect (11.061.1 mV, n= 5). However, the
residual EDH was suppressed by the KCa1.1 (BKCa) blocker,
iberiotoxin (100 nM; 4.060.5 mV, n= 5; Figure 2B). In the
presence of U46619 if arteries were exposed to the Rho kinase
inhibitor, Y27632 (10 mM: control hyperpolarization to
SLIGRL, 26.263.14 mV, plus Y27632 26.564.2 mV, n= 8),
despite a trend toward block, TRAM-34 did not significantly
inhibit EDH (16.261.9 mV, n= 8). However, the subsequent
addition of apamin significantly inhibited EDH (to 6.961.0 mV,
n= 6, P,0.05). The residual hyperpolarization was again
inhibited further by iberiotoxin, as in the absence of Y27632
(3.460.2 mV, n= 5; Figure 2C). These results indicate that
stimulation of TP receptors with U46619 inhibits KCa2.3
function and that subsequent inhibition of Rho kinase restores
or protects this component of hyperpolarization.
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Inhibiting Rho Kinase Restores the Input of KCa2.3 to EDH
in the Presence of a NO Synthase Inhibitor
Previous studies demonstrate that in the presence of the NOS
inhibitor L-NAME (100 mM) the MCA constricts and EDH is
blocked by TRAM-34 alone indicating a critical role for KCa3.1
[1]. In this study 100 mM L-NAME contracted cerebral arteries
and a higher concentration of L-NAME (300 mM) had no
additional constrictor effect (data not shown). In the presence of
L-NAME the EDH responses were completely inhibited by
TRAM-34 alone (Figure S1) confirming that under these
conditions only KCa3.1 contributes to EDH. The contraction
was reversed by SLIGRL (to stimulate EDH and associated
relaxation of 21.463.9 mV and 67.966.1%, respectively n= 6;
Figure 3A, E). Addition of the Rho kinase inhibitor Y27632
(10 mM) also reversed the L-NAME induced constriction
(relaxation of 86.062.4%, n= 6) and the subsequent relaxation
to SLIGRL became too small to assess accurately (Figure 3B).
In contrast, EDH was unaffected by Y27632 (18.561.9 mV to
20 mM SLIGRL, n= 5), and TRAM-34 now only partially
reduced this hyperpolarization (10.662.2 mV, n= 4, P,0.05;
Figure 3C,E). The residual hyperpolarization was abolished by
the additional presence of apamin (0.261.8 mV, n= 4, P,0.05;
Figure 3D, E). A structurally distinct and extremely selective
Rho kinase inhibitor SR5037 [20] had a similar effects to
Y27632. This novel agent reversed vasoconstriction to L-NAME
(relaxation of 85.263.7% n=4) and the remaining tension was
too small to assess accurately. SR5037 also restored the KCa2.3
component to EDH, as TRAM-34 failed to completely block
hyperpolarization and the combination of TRAM-34 and
apamin were both required to block hyperpolarization
(Figure 3F). Thus, in the presence of L-NAME block of
KCa3.1 with TRAM-34 alone inhibits the EDH response.
Inhibition of Rho kinase with selective and structurally distinct
inhibitors reveals a KCa2.3 input to EDH responses indicating
that Rho kinase normally supresses the function of these
channels in the presence of L-NAME.
Simvastatin Prevented Loss of KCa2.3 Input to EDH
Following TP Receptor Stimulation
In MCAs able to synthesise NO inhibition of Rho kinase with a
selective inhibitor protected KCa2.3 function against TP receptor
stimulation produced by U46619. In a separate group of
experiments in vessels able to synthesise NO and stimulated with
U46619 (50–100 nM) we assessed if statins shared this effect of
Rho kinase inhibitors. SLIGRL (20 mM) evoked EDH of
30.965.9 mV (n= 7). This response was not modified by
100 nM simvastatin (31.864.4 mV, n= 7). Subsequently, EDH
was not reduced with TRAM-34 (25.466.4 mV, n= 4), but was
progressively and significantly reduced by adding apamin and then
iberiotoxin EDH (to 15.862.9 mV, n= 4, P,0.05 then
4.160.5 mV, n= 3, P,0.05; Figure 4A). At a higher concentra-
tion simvastatin (1 mM) again did not modify EDH evoked in the
Figure 1. Expression of the TP receptor in the endothelium of rat middle cerebral arteries. A) RT-PCR amplification of mRNA transcripts
for TP receptor (439 bp) and KCa2.3 channels (514 bp) from rat MCA. bp=base pairs B) Localization of TP receptor and PECAM-1-immunoreactivity in
whole mount preparations of rat MCA. TP receptor-immunoreactivity was present in the endothelial cell layer (PECAM-1-positive). Orientation of cell
nuclei was determined using DAPI. The merged image demonstrates coexpression of TP receptors and PECAM-1, indicating TP receptor expression in
the endothelial cells of rat MCAs. Scale bar, 20 mm.
doi:10.1371/journal.pone.0046735.g001
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presence of U46619 (at 24.664.6 mV and 26.664.0 mV, pre and
post simvastatin respectively, n = 8), and a similar inhibitory profile
was observed with KCa channel blockers, EDH of 15.262.9 mV,
n= 8 with TRAM-34, 6.561.0 mV, n= 5, P,0.05 with apamin
and 4.060.9 mV, n= 5, P,0.05 with iberiotoxin (Figure 4B).
Simvastatin (100 nM or 1 mM) did not significantly alter U46619
induced tone; however a higher concentration of simvastatin
(10 mM) fully relaxed tone (data not shown). Normally there is no
KCa2.3 component to hyperpolarization in the presence of
U46619 but in the presence of simvastatin, at either concentration,
blockade of this channel was required to significantly inhibit
hyperpolarization. Thus a statin, like the Rho kinase inhibitor,
protects the KCa2.3 component to EDH from TP receptor
stimulation.
Simvastatin and Lovastatin Restore the Input of KCa2.3 to
EDH in the Presence of a NO Synthase Inhibitor while
Geranylgeranyl-pyrophosphate Circumvents this
Protection
In rat MCAs treated with L-NAME we assessed if statins shared
the effect of Rho kinase inhibitors to restore the KCa2.3
component of EDH. EDH and relaxation to SLIGRL was
30.763.5 mV and 75.564.1%, respectively (n = 8 Figure 5E). In
Figure 2. Effect of inhibition of Rho Kinase on TP induced constriction and EDH responses obtained in the presence of TP
stimulation in the rat middle cerebral artery. (A) Concentration response curve showing the vasoconstrictor response produced by the
thromboxane A2 mimetic U46619 (1 nM-1 mM; n= 5) in rat middle cerebral arteries in the presence and absence of the selective Rho kinase inhibitor
Y27632 (1 and 10 mM; n= 5). Inhibition of Rho kinase significantly and concentration dependently reduced the maximum constriction produced by
U46619 and significantly shifted the concentration response curve to the right. (B) Histogram showing SLIGRL (20 mM) induced EDH evoked in the
presence of U46619 (50–100 nM) in vessels able to synthesise NO. Also shown are EDH in the presence of KCa3.1 blockade (1 mM, TRAM-34), blockade
of both KCa2.3 and 3.1 (100 nM apamin+TRAM-34) and blockade of KCa1.1, 2.3 and 3.1 (100 nM Iberiotoxin+apamin+TRAM-34). Block of KCa3.1 alone
was sufficient to significantly reduce EDH; subsequent block of KCa2.3 had no further effect indicating this channel was not functional. Residual EDH
was inhibited by further blockade of KCa1.1. (C) Histogram showing SLIGRL induced EDH in the presence of U46619 and the Rho Kinase inhibitor
Y27632 in vessels able to synthesise NO. EDH was only significantly reduced following combined blockade of both KCa3.1 and 2.3, indicating that the
KCa2.3 channel was now functional. *P,0.05 indicates a significant difference from control (U46619 alone) using one-way ANOVA with Tukey’s post-
test, n = 5–6) wP,0.05 indicates a significant difference from Y27632 as determined by one-way ANOVA with Tukey’s post-test, n = 5–6.
doi:10.1371/journal.pone.0046735.g002
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Figure 3. Original traces showing the isolated EDH response evoked by SLIGRL (20 mM) in rat MCAs treated with the NOS inhibitor
L-NAME (100 mM). Upper panels show Em, lower panels tension. (A) Control EDH response. (B) EDH response in the presence of the Rho kinase
inhibitor Y27632 (10 mM). (C) EDH response in the presence of Y27632 and the KCa3.1 blocker, TRAM-34 (1 mM). (D) EDH response in the presence of
Y27632, TRAM-34 and the KCa2.3 blocker apamin (100 nM). (E) Histogram showing SLIGRL-induced EDH in the presence of Y27632 (10 mM), Y27632
and TRAM-34 and the combination of Y27632, TRAM-34 and apamin. (F) Histogram showing SLIGRL-induced EDH mediated hyperpolarization in the
presence of SR5037 (1 mM), SR5037 and TRAM-34 and the combination of SR5037, TRAM-34 and apamin. Both Y27632 and SR5037 fully relaxed L-
NAME induced tone, hyperpolarization was unaffected. Normally in the presence of L-NAME blockade of KCa3.1 is sufficient to block the EDH
response, however following inhibition of Rho kinase subsequent inhibition of KCa2.3 is required to fully block the EDH response. *P,0.05 indicates a
significant difference from control, one-way ANOVA with Tukey’s post-test, n = 4–6. wP,0.05 indicates a significant difference from Rho kinase
inhibitor alone (Y27632 or SR5037) as determined by one-way ANOVA with Tukey’s post-test, n = 4–6.
doi:10.1371/journal.pone.0046735.g003
Rho Kinase, Statins and Vascular KCa2.3 Function
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the presence of 100 nM simvastatin this was unchanged
(28.263.8 mV, n= 7, and 74.263.0%, n= 8; Figure 5A, E).
TRAM-34 then significantly attenuated hyperpolarization and
relaxation (to 14.864.0 mV and 56.464.2%, respectively, n = 8,
P,0.05; Figure 5B, E). The subsequent addition of apamin further
attenuated these responses (to 7.761.6 mV and 36.568.5%,
n= 6, P,0.05; Figure 5C,E) as did iberiotoxin (to 2.763.9 mV
and 21.167.0%, n= 4, P,0.05; Figure 5D, E). Both 1 mM
simvastatin (figure 5F) or 100 nM Lovastatin (Figure S2) had a
similar influence i.e. a combination of TRAM-34 and apamin was
required to significantly to block the EDH response (Figure 5F and
Figure S2). Normally in the presence of L-NAME, TRAM-34
alone can block the EDH response (Figure S1). In the presence of
statins the additional requirement of apamin to fully inhibit EDH
indicate these agents share the ability of Rho kinase inhibitors to
protect KCa2.3 function.
Further experiments were conducted to assess the potential
mechanisms by which statins protect KCa2.3 function in arteries
treated with L-NAME. EDH and relaxation to SLIGRL
(23.963.2 mV and 76.962.9%, n= 4) was not altered by
simvastatin (100 nM; 22.565.5 mV and 76.662.3%, n= 4) or
by the combination of simvastatin and isoprenoid GGPP (1 mM;
21.362.4 mV and 76.267.1%, n= 4). However, with GGPP
present EDH responses were virtually abolished by the addition of
TRAM-34 alone (3.961.6 mV and 16.366.5%, n= 4, P,0.05;
Figure 6). As GGPP only restores the isoprenylation pathway and
not cholesterol synthesis [28] the ability of statins to protect
KCa2.3 function is likely to be a pleiotropic effect independent of
effects on cholesterol synthesis.
Discussion
These data implicate a novel role for Rho kinase in mediating
TP receptor-dependent regulation of KCa2.3 channel function in
EDH and associated smooth muscle cell relaxation in the rat
MCA. They provide a mechanistic explanation for our previous
observation that NO can protect KCa2.3 function in this artery by
suppressing TP receptor signalling [6] and that stimulation of TP
receptors can inhibit KCa2.3 function [6,7,29]. Our data also show
that statins [21] restore KCa2.3 input to EDH and that this action
is independent of effects on synthesis of cholesterol, possibly
reflecting inhibition of Rho-mediated signalling.
To record and quantify the EDH response it is necessary to
block NOS. In most arteries inhibition of EDH requires combined
block endothelial cell KCa2.3 and 3.1 channels [3] Unusually, the
rat MCA displays an EDH response that is solely due to KCa3.1
activation, as inhibition of KCa3.1 abolished EDH regardless of
the agonist used to stimulate the EDH response [1,2]. However,
MCAs express both KCa2.3 and KCa3.1 channel protein [4,5]. An
explanation for this apparent paradox is that KCa2.3 can
contribute to EDH, but only when the artery is able to synthesize
NO, i.e. in the absence of a NOS inhibitor [5]. KCa2.3 also
contributes to EDH in the presence of a NOS inhibitor, provided
that TP receptors are antagonized [6]. In each case, inhibition of
KCa2.3 alone had no discernible effect, but inhibition of EDH was
now only significant following inhibition of both KCa2.3 and
KCa3.1. The mechanism by which TP receptors selectively
suppressed KCa2.3 function was not clear.
TP receptors couple to several second messenger systems,
particularly PLC [30], and small GTPases such as Rho [31,32]. In
vascular smooth muscle cells, both these pathways contribute to
constriction, but Rho-mediated pathways predominate [13], block
of U46619-mediated constriction confirms this in the MCA. We
demonstrate that TP receptors are also located on endothelial cells
of the MCA (Figure 1). As KCa2.3 are only expressed in the
endothelium of this artery [5], TP receptors could potentially
selectively regulate the function of this channel by Rho kinase-
dependent mechanisms.
We assessed the role of Rho kinase in regulation of KCa2.3
channels in MCAs able to synthesise NO. Under these conditions
stimulation of TP receptors causes a loss of function of KCa2.3
channel [6]. We now show that inhibiting Rho kinase with
Y27632 can ‘‘protect’’ or restore the KCa2.3 input to EDH that is
blocked in the presence of the TP receptor agonist, U46619
Figure 4. Histograms showing EDH evoked by SLIGRL (20 mM) in rat MCAs that are able to synthesise NO but treated with the TP
receptor agonist, U46619 (50–100 nM). Also shown is the effect of the HMG-CoA reductase inhibitor simvastatin at either 100 nM (A) or 1 mM (B)
on EDH and the effect of blocking KCa3.1 alone (TRAM-34, 1 mM), in the subsequent presence of blockade of both KCa2.3 (apamin 100 nM) and KCa3.1
as well as the combined of blockade of KCa1.1 (iberiotoxin 100 nM), K-Ca2.3 and KCa3.1. *P,0.05 indicates a significant difference from control using
one way ANOVA with Tukey’s post-test, n = 4–7. wP,0.05 indicates a significant difference from simvastatin (100 nM or 1 mM) as determined by one-
way ANOVA with Tukey’s post-test, n = 4–7.
doi:10.1371/journal.pone.0046735.g004
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(Figure 2C). It is important to note that the residual KCa1.1
component of EDH seen in these conditions is NO mediated [10].
In the absence of NO synthesis (i.e. in the presence of L-NAME),
EDH was blocked with TRAM-34 (Figure S2), indicating that
KCa3.1 channels alone underpinned hyperpolarization, as previ-
ously reported [1]. In the presence of either Y27632 or a
structurally distinct and highly selective Rho kinase inhibitor,
SR5037 [20], TRAM-34 now failed to fully block EDH (Figure 3);
Figure 5. Effect of simvastatin on isolated EDH responses obtained in the presence of a NO synthase inhibitor. (A–D) Original traces
showing the effect of 100 nM simvastatin (A) on isolated SLIGRL-induced EDH-mediated responses (hyperpolarization, upper panels; relaxation, lower
panels) obtained in rat MCAs treated with the NOS inhibitor L-NAME (100 mM). Also shown is the effect of block of KCa3.1 (TRAM-34; B); combined
block of KCa2.3 and 3.1 with apamin and TRAM-34 (C) and the further blockade of KCa1.1, 2.3 and 3.1 with iberiotoxin, apamin and TRAM-34 (D). Also
shown (E–G) are histograms of the mean data for SLIGRL-induced EDH mediated responses (hyperpolarization, upper panels; relaxation, lower panels)
in the presence of 100 nM simvastatin (E), 1 mM simvastatin (F). Normally in the presence of L-NAME inhibition of KCa3.1 alone is sufficient to block
the EDH response. However, statins revealed a KCa2.3 component to the EDH response. *P,0.05 indicates a difference from control,
wP,0.05
indicates a significant difference from simvastatin (100 nM or 1 mM) as determined by one-way ANOVA with Tukey’s post-test, n = 5–8.
doi:10.1371/journal.pone.0046735.g005
Figure 6. Effect of restoring the isoprenoid signalling pathway on EDH responses obtained in the presence of simvastatin and a NO
synthase inhibitor. (A–D) original traces showing isolated SLIGRL-induced, EDH-mediated hyperpolarizations (upper panels) and relaxations (lower
panels) obtained from rat MCAs treated with the NOS inhibitor L-NAME (100 mM; A). Also shown is the additional effect of simvastatin (100 nM),
addition of GGPP (1 mM; C) and the combination of simvastatin and GGPP with the KCa3.1 inhibitor TRAM-34 (1 mM; D). (E) Histogram showing the
mean data for isolated EDH-mediated responses (hyperpolarization, upper panel; relaxation, lower panel). While GGPP did not alter the total EDH
mediated response it reversed the ability of simvastatin to protect KCa2.3 function as inhibition of KCa3.1 with TRAM-34 alone was sufficient to
significantly inhibit the EDH response. *P,0.05 indicates a significant difference from control using one-way ANOVA with Tukey’s post-test, n = 4.
wP,0.05 indicates a significant difference from simvastatin, as determined by one-way ANOVA with Tukey’s post-test, n = 4.
doi:10.1371/journal.pone.0046735.g006
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EDH was only fully blocked if KCa2.3 channels were subsequently
inhibited with apamin (Figure 3D–F). It was impossible to measure
effect on EDH mediated relaxation as Rho kinase inhibition fully
relaxed tone (Figure 3B). Thus, inhibition of Rho kinase restores
the KCa2.3 component of EDH, indicating that TP signalling
through Rho kinase negatively and selectively modulates KCa2.3
(Figure 7). Inhibition of Rho kinase also reduced the constriction
produced by blockade of NOS implying that Rho kinase is
involved in this response, which is perhaps unsurprising since TP
receptor stimulation is implicated in the constriction produced by
NOS inhibitors in the MCA [33,34].
As Rho kinase appears to inhibit endothelial cell KCa2.3
function, we postulated statins might act to ‘protect’ the input of
these channels in a similar manner to the Rho kinase inhibitors. As
a consequence of inhibiting HMG-CoA reductase, statins also
inhibit Rho kinase [35]. This ‘‘pleiotropic’’ effect is explained by
an ability to prevent isoprenylation and subsequent translocation
to the membrane of GTPases, such as Rho, an effect reversed by
addition of exogenous isoprenoids [15,23]. This appeared to be
the case, in arteries able to synthesise NO and exposed to the TP
receptor agonist U46619 (to inhibit KCa2.3) the statin, simvastatin
(100 nM and 1 mM) restored the input of KCa2.3 to EDH
(Figure 4). Simvastatin also restored KCa2.3 input to EDH-
mediated responses once NOS was blocked (Figure 5A–F); a
response that normally reflects only the activity of KCa3.1 (Figure
S1) [1]. A structurally distinct statin, lovastatin had similar effects
(Figure S2). At 100 nM simvastatin seemed to reveal a KCa1.1
component to EDH that was absent at a higher concentrations or
with lovastatin. NO synthesis was inhibited in these experiments so
this probably reflects an ability of this lower concentration of
simvastatin to directly stimulate this channel [36].
The restorative action of the statins on KCa2.3 function is
unlikely to reflect a reduction in cholesterol synthesis as this mainly
occurs in the liver [28]. However, arteries do express HMG-CoA
reductase [37], inhibition of which reduces production of
isoprenoids including geranylgeranylpyrophosphate (GGPP) [28].
GGPP acts as a post-translational lipid attachment essential for the
function of many proteins including Rho, rac and cd42 [28,38].
Exogenous GGPP circumvented the ability of statins to restore
KCa2.3 function (Figure 6). Therefore, statins protect KCa2.3
channel function by inhibiting isoprenylation. As reductions in
isoprenylation reduce Rho signalling we speculate this is the
mechanism by which statins protect KCa2.3 function. Indeed,
inhibition of Rho is the mechanism by which statins augment
NOS function in endothelial cells [15,23]. Although the concen-
trations of statins used in this study did not produce powerful
vasodilator responses seen with the inhibitors of Rho kinase,
higher concentrations of statins (.1 mM) do cause relaxation (data
not shown). Perhaps this indicates that the lower, clinically
relevant concentrations [21] used in this study are not sufficient to
fully inhibit Rho signalling in smooth muscle cells.
It is important to note we used the closed ring (lactone) form of
simvastatin (and lovastatin) in this study. These require hydrolysis
to the open ring Na+ salt (acid) form to inhibit HMG-CoA. [39] a
process that occurs rapidly in rodent plasma [40]. While it is
unknown if it this can also occur in arterial tissues CYP450
enzymes can dehydrogenate lovastatin (and simvastatin) [41] to
the open acid form and the CYP3A4 subtype involved has been
shown to be expressed in monkey endothelial cells [42].
Regardless, in this study GGPP reversed the effects of the lactone
version of simvastatin indicating that the effects were mediated via
inhibition of HMG Co-A. This is supported by a previous report
in porcine vascular smooth muscle cells where the lactone form of
Figure 7. Schematic diagram showing potential regulatory mechanisms of KCa2.3 channels by TP receptor/rho mediated signalling.
Increased stimulation of the TP receptor with the agonist U46619 or following inhibition of NOS (eNOS) with L-NAME (NO can supress the action of TP
receptors or synthesis of metabolites that activate TP) (1) results in activation of rhoA and stimulation of Rho kinase (2). Rho kinase (or associated
signalling) inhibits KCa2.3 function (3) and inhibitors of Rho kinase (Y27632 or SR5037) restore or protect the KCa2.3 component of EDH (4). Statins by
inhibiting HMG-CoA prevent formation of the isoprenoid GGPP (5). This reduces Rho mediated signalling by preventing GGPP dependent
translocation of rhoA to the plasma membrane (6). Therefore statins protect KCa2.3 function by inhibiting Rho-mediated signalling via the TP receptor
(1–3.). Red arrows/text indicates an inhibitory mechanism. Green text/arrows represent a stimulatory mechanism. Blue arrows indicate synthetic
pathways; dashed blue line indicates translocation to the plasma membrane.
doi:10.1371/journal.pone.0046735.g007
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simvastatin mediated effects dependent on inhibition of HMG Co-
A [36].
Although our data strongly suggest a regulatory role for rho
kinase on endothelial cell KCa2.3 channel input to EDH, it
remains to be determined how Rho/Rho kinase inhibits KCa2.3. It
is possible regulation involves direct phosphorylation of the
channel by Rho kinase, or an associated kinase, similar to the
regulation of KCa3.1 channels by kinases in immune cells [43].
Alternatively, Rho kinase might indirectly modulate KCa2.3 by
remodelling the cytoskeleton; delayed rectifier channels in cerebral
artery smooth muscle cells are inhibited by actin polymerization
that is Rho kinase dependent [44].
Whatever the precise mechanism, vasoconstrictors such as TP,
endothelin-1 and angiotensin II signal via the Rho kinase pathway
and receptors for these vasoconstrictors are present on endothelial
cells [14,45,46]. As a number of models of hypertension and
diabetes are associated with an increased production/function of
these vasoconstrictors it is perhaps not surprising that EDH-
mediated signalling is suppressed [47]. The ability of statins to
protect endothelial cell KCa function appears to involve isopren-
oids and Rho-mediated signalling; such protection may help to
explain the beneficial effect of statin treatment after stroke [48]. As
Rho signalling inhibits a vital component of EDH, KCa2.3
channels located on the endothelium, our data support the
rationale for treating endothelial dysfunction and related disorders
by targeting Rho signalling.
Supporting Information
Figure S1 Histograms of the mean data for SLIGRL-
induced EDH (hyperpolarization, upper panels; relaxa-
tion, lower panels) in the presence of the NOS inhibitor
L-NAME (100 and 300 mM). The EDH responses were
completely abolished by the KCa3.1 blocker TRAM-34 (1 mM).
*P,0.05 indicates a significant difference from the 100 mM L-
NAME control group; n= 3.
(TIF)
Figure S2 Histograms of the mean data for SLIGRL-
induced EDH mediated (hyperpolarization, upper pan-
els; relaxation, lower panels) in the presence of the NOS
inhibitor L-NAME (100 mM) and the subsequent effect of
the statin lovastatin (100 nM). Normally in the presence of L-
NAME inhibition of KCa3.1 alone is sufficient to block the EDH
response. However, lovastatin revealed a KCa2.3 component to
the EDH response. *P,0.05 indicates a difference from control,
wP,0.05 indicates a significant difference from lovastatin as
determined by one-way ANOVA with Tukey’s post-test, n = 5.
(TIF)
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